Home  /  Resource Library  /  Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

Results of a study investigating ibrutinib combined with venetoclax for first line treatment of chronic lymphocytic leukemia.